Essay on "Pharma Joan Busfield (N.D.) Explores the Pharmaceutical"

Essay 4 pages (1293 words) Sources: 1+

[EXCERPT] . . . .

Pharma

Joan Busfield (n.d.) explores the pharmaceutical industry as a source of rising health costs. She identifies a few different issues. One of these is the monopoly that pharmaceutical companies have over the drugs they develop, which lasts 20 years and is designed to allow them to earn back the cost of drug development. Another issue that pharmaceuticals are overprescribed -- one of per month for everybody in the developed world. While drug makers earn high profit levels in the west, developing nations are under pressure from bodies like the World Trade Organization to accept Western standards for intellectual property rights, which would force firms in the developing world to produce old, generic products almost exclusively, or pay licensing fees that would put those products out of reach pricewise for most of the people in those countries.

Busfield in particular calls attention to the lack of study regarding pharmaceuticals as consumer products, despite the size of the world's largest pharma companies and their influence of global social outcomes. She seeks specifically to call attention to the power and influence of the pharmaceutical industry in public and political discourse, and policy-making. She notes that while some within the industry complain about the costs associated with drug-testing for approval, many aspects of the process are designed to serve the needs of industry, rather than consumers.

Abraham (n.d.) postulates the idea of "pharmaceuticalization," which he defines as "the process by which social, behavioral or bodily conditions are treated…with pharmaceuticals" (p.290). He argues that the political economy of the pharmaceutical industry, consumerism and deregulatory state ideology are all contributing factors, interrelated, that drive the commercial success of the pharmaceutical industry. Abraham's overarching point is that these factors, more than medical necessity, are what have driven the increased use of pharmaceuticals and therefore health care costs.

Monopoly

The FDA has a multi-stage process by which it approves new drugs. This process, in general, takes several years and hundreds of millions of dollars to bring a product to market. Most new products that begin this process never reach FDA approval, meaning that they never come to market. For pharmaceutical companies, there is little incentive to invest in drug development in a totally free market, because after spending this time and money to develop a drug they would see competitors isolate the chemical composition of their work and replicate that drug within months or even weeks. The solution to this issue is the monopoly.

The monopoly is basic economics -- without competition, the firm can set its prices wherever it feels it will gain the highest profits. The pharmaceutical companies receive a 20-year monopoly on new drugs, which they view as an opportunity not only to recoup the cost of developing that drug, but the costs associated with developing other drugs that did not make it through the approval process, plus a profit margin on top of that. These are paid by the federal government through Medicare and Medicaid, and by insurance companies. In other words, these costs are paid by taxpayers, employers and consumers. The tradeoff is simple -- these payers are able to have some (if limited) access to a drug in exchange for paying inflated costs for it. The idea is that without the monopoly, pharmaceutical companies are unlikely to innovate new drugs.

The problem with monopoly is that it limits supply in the market. Thus, it serves the needs of suppliers, but not the needs of consumers. An efficient market has multiple competitors, and the price will trend towards equilibrium. The problem is that there is no efficient market in health care, and the distortions are cause runaway prices, and a drug-addled society. On the former, monopoly is always going to result in inflated prices. The issue with high prices is that it cuts out a segment of the market that is unable to pay. It must be remembered… READ MORE

How to Reference "Pharma Joan Busfield (N.D.) Explores the Pharmaceutical" Essay in a Bibliography

Related Essays:

Systems Roelofs (N.D.) Defines an Open Essay

Systems

Roelofs (n.d.) defines an open system as "any distinct entity that takes in resources from its environment, processes them in some way, and produces output." By this definition, both… read more

Essay 4 pages (1185 words) Sources: 2 Topic: Military / Army / Navy / Marines

---

Joan Miro's Detailist Period Term Paper

Joan Miro's Detailist Period

Joan Miro was born on April 20, 1893 and began drawing classes in 1900 (Fundacio Miro, p.1). By his early teens, his skill as an artist… read more

Term Paper 7 pages (2837 words) Sources: 7 Topic: Art / Painting / Sculpture

---

Pharmaceutical Companies Intellectual Property and the Global AIDS Epidemic Research Paper

Pharmaceutical Companies, Intellectual Property and the Global AIDS Epidemic

Over the last several years, there has been a focus in the world community on providing many developing nations with low… read more

Research Paper 8 pages (2455 words) Sources: 5 Topic: Medicine / Pharmacy

---

Pharmaceutical Tangible and Intellectual Property Term Paper

Pharmaceutical Property

Intellectual and Tangible Property Rights and the Pharmaceutical Industry: Current Rends and General management

Protecting Tangible Property Rights

Protecting its tangible property is one of the most essential… read more

Term Paper 3 pages (825 words) Sources: 4 Style: APA Topic: Copyright / Trademark / Patent

---

Diagnosis Miller and Geissbuhler (N Discussion Chapter

Diagnosis

Miller and Geissbuhler (n.d.) define diagnosis as "the placing of an interpretive, higher level label on a set of raw, more primitive observations" thereby treating diagnosis as a single… read more

Discussion Chapter 2 pages (674 words) Sources: 3 Topic: Healthcare / Health / Obamacare

---

View 100+ more related papers  >>